CG Invites Co., Ltd. (KOSDAQ:083790)
South Korea
· Delayed Price · Currency is KRW 1,355.00
-101.00 (-6.94%)
Mar 9, 2026, 3:30 PM KST
CG Invites Revenue
CG Invites had revenue of 6.13B KRW in the quarter ending September 30, 2025, with 276.19% growth. This brings the company's revenue in the last twelve months to 18.12B, up 225.13% year-over-year. In the year 2024, CG Invites had annual revenue of 7.25B with 48.67% growth.
Revenue (ttm)
18.12B
Revenue Growth
+225.13%
P/S Ratio
5.75
Revenue / Employee
172.59M
Employees
105
Market Cap
104.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.25B | 2.37B | 48.67% |
| Dec 31, 2023 | 4.88B | 557.33M | 12.90% |
| Dec 31, 2022 | 4.32B | -38.05B | -89.80% |
| Dec 31, 2021 | 42.38B | 12.15B | 40.21% |
| Dec 31, 2020 | 30.22B | 16.22B | 115.78% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IMB Dx | 4.26B |
| Amicogen | 87.97B |
| GeneOne Life Science | 30.90B |
| Oncocross | 884.68M |
| ENCell | 5.91B |
| ORIENT BIO | 59.09B |
| Macrogen | 179.98B |
| Vaxcell-Bio Therapeutics | 1.90B |